BeiGene Approved to Stage $3 Billion IPO on Shanghai STAR Exchange
publication date: Jun 30, 2021
BeiGene of Beijing has reportedly been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong and the US. According to a Caixin report, BeiGene’s prospectus meets the listing conditions and information disclosure requirements of the STAR Market, but regulators asked BeiGene to explain how it will protect the interests of domestic shareholders. Founded in 2010, BeiGene develops molecularly targeted and immuno-oncology drug candidates to treat cancer. More details....
Stock Symbols: (NSDQ: BGNE; HK: 06160)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.